Administration of Protein-Conjugate Pneumococcal Vaccine to Patients Who Have Invasive Disease after Splenectomy Despite Their Having Received 23-Valent Pneumococcal Polysaccharide Vaccine

Patients who undergo splenectomy are at greatly increased risk for overwhelming pneumococcal bacteremia and death. Twenty-three–valent pneumococcal polysaccharide vaccine (PPV-23), which contains capsular polysaccharides (PSs) from 23 common serotypes of Streptococcus pneumoniae is strongly recommen...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of infectious diseases Vol. 191; no. 7; pp. 1063 - 1067
Main Authors Musher, Daniel M., Ceasar, Heather, Kojic, Erna M., Musher, Benjamin L., Gathe, Joseph C., Romero-Steiner, Sandra, White, A. Clinton
Format Journal Article
LanguageEnglish
Published Chicago, IL The University of Chicago Press 01.04.2005
University of Chicago Press
Oxford University Press
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Patients who undergo splenectomy are at greatly increased risk for overwhelming pneumococcal bacteremia and death. Twenty-three–valent pneumococcal polysaccharide vaccine (PPV-23), which contains capsular polysaccharides (PSs) from 23 common serotypes of Streptococcus pneumoniae is strongly recommended for such patients. The capacity to respond to PPV-23 by producing immunoglobulin (Ig) G is genetically regulated. Some proportion of adults do not respond and, despite postsplenectomy administration of PPV-23, may remain susceptible to recurrent pneumococcal sepsis. Here, we describe 2 patients who had recurring pneumococcal bacteremia after undergoing splenectomy despite having received numerous doses of PPV-23. Heptavalent protein-conjugate pneumococcal vaccine (PCPV-7) was then administered, and it induced high levels of IgG to all 7 PSs; in one of the patients, functional activity against 5 of the 7 PSs was demonstrable, both in vitro and in vivo. Recurrent pneumococcal bacteremia in patients who have undergone splenectomy may indicate a genetically regulated failure to respond to PPV-23; PCPV-7 may stimulate production of IgG to PSs in such patients
Bibliography:ark:/67375/HXZ-DP9WP6MX-1
istex:5BEC35AF801A11A6904E88E73233A8BC1888A9C8
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Case Study-3
ObjectType-Article-1
ObjectType-Feature-4
ObjectType-Report-2
ISSN:0022-1899
1537-6613
DOI:10.1086/428135